Pathological role of a point mutation (T315I) in BCR‐ABL1 protein—A computational insight
作者： Vidya Rajendran , Chandrasekhar Gopalakrishnan , Rao Sethumadhavan
DOI: 10.1002/JCB.26257
关键词: Point mutation 、 Computational biology 、 Protein A 、 Chemistry 、 Mechanism (biology) 、 Mutation (genetic algorithm) 、 Tyrosine kinase 、 Genetics 、 Threonine 、 Myeloid leukemia 、 Mutant
摘要: … BCR-ABL1 and … ABL1 T315I but also suppresses the uncontrolled cell division effectively. The pathological condition associated with BCR-ABL1 mutation (T315I) is depicted in Figure 1. …
sci-hub.se 参考文章(35)
Maria Pérez-Caro, Isidro Sánchez-Garcia, BCR-ABL and Human Cancer Apoptosis, Cell Signaling, and Human Diseases. pp. 3- 34 ,(2007) , 10.1007/978-1-59745-200-7_1
Mary Alikian, Gareth Gerrard, Papagudi G. Subramanian, Katherine Mudge, Pierre Foskett, Jamshid Sorouri Khorashad, Ai Chiin Lim, David Marin, Dragana Milojkovic, Alistair Reid, Katy Rezvani, John Goldman, Jane Apperley, Letizia Foroni, BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. American Journal of Hematology. ,vol. 87, pp. 298- 304 ,(2012) , 10.1002/AJH.22272
Berk Hess, Carsten Kutzner, David van der Spoel, Erik Lindahl, GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation Journal of Chemical Theory and Computation. ,vol. 4, pp. 435- 447 ,(2008) , 10.1021/CT700301Q
Elias Jabbour, Jorge Cortes, Hagop Kantarjian, Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review Core Evidence. ,vol. 4, pp. 207- 213 ,(2009) , 10.2147/CE.S6003
B. J. Alder, T. E. Wainwright, Studies in Molecular Dynamics. I. General Method The Journal of Chemical Physics. ,vol. 31, pp. 459- 466 ,(1959) , 10.1063/1.1730376
Vidya Rajendran, Rao Sethumadhavan, Drug resistance mechanism of PncA inMycobacterium tuberculosis Journal of Biomolecular Structure and Dynamics. ,vol. 32, pp. 209- 221 ,(2014) , 10.1080/07391102.2012.759885
Moshe Talpaz, Neil P. Shah, Hagop Kantarjian, Nicholas Donato, John Nicoll, Ron Paquette, Jorge Cortes, Susan O'Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath Iyer, Tai-Tsang Chen, Fei Huang, Arthur P. Decillis, Charles L. Sawyers, Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias The New England Journal of Medicine. ,vol. 354, pp. 2531- 2541 ,(2006) , 10.1056/NEJMOA055229
Mercedes E Gorre, Mansoor Mohammed, Katharine Ellwood, Nicholas Hsu, Ron Paquette, P Nagesh Rao, Charles L Sawyers, Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification Science. ,vol. 293, pp. 876- 880 ,(2001) , 10.1126/SCIENCE.1062538
Louis J. Lombardo, Francis Y. Lee, Ping Chen, Derek Norris, Joel C. Barrish, Kamelia Behnia, Stephen Castaneda, Lyndon A. M. Cornelius, Jagabandhu Das, Arthur M. Doweyko, Craig Fairchild, John T. Hunt, Ivan Inigo, Kathy Johnston, Amrita Kamath, David Kan, Herbert Klei, Punit Marathe, Suhong Pang, Russell Peterson, Sidney Pitt, Gary L. Schieven, Robert J. Schmidt, John Tokarski, Mei-Li Wen, John Wityak, Robert M. Borzilleri, Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry. ,vol. 47, pp. 6658- 6661 ,(2004) , 10.1021/JM049486A
Massimo Breccia, Giuliana Alimena, Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia Leukemia Research. ,vol. 34, pp. 129- 134 ,(2010) , 10.1016/J.LEUKRES.2009.08.031